Overview

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Status:
Recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

This is a randomized, open label Phase II-III neoadjuvant study comparing the efficacy and safety of ARX788 combined with pyrotinib maleate versus TCBHP (trastuzumab plus pertuzumab with docetaxel and carboplatin) in patients with HER2-positive breast cancer.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Caigang Liu

Collaborators:

Jiangsu HengRui Medicine Co., Ltd.
NovoCodex Biopharmaceuticals Co., Ltd.

Treatments:

Carboplatin
Docetaxel
Pertuzumab
Trastuzumab